Change over period: —
NSE · RUBICON
RUBICON
-10.9% from the 52-week high · +169.6% above the low
Rubicon Research Ltd is a pharmaceutical research and development company engaged in drug development, contract research, and manufacturing. It provides end-to-end services to global pharmaceutical clients, from early-stage discovery to clinical trials and regulatory support. Its capabilities include formulation development, bioanalytical studies, and manufacturing of active pharmaceutical ingredients. The company leverages its scientific expertise to deliver innovative and reliable solutions to the healthcare industry.
The short version. RUBICON reported revenue of ₹576 crore for Sep 2026, up 39.8% from a year earlier. Net profit was ₹90 crore (up 66.7% year on year). Return on equity was 19.1% in Mar 2026. Promoter holding was 51.24% in Sep 2026, down 8.75 points over 5 quarters.
1 · The price
How has the stock traded?
RUBICON trades 10.9% below its 52-week high and 169.6% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹576 cr.
Sep 2026 net profit of ₹90 cr.
2.6 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Revenue | 576 | 534 | 514 | 476 | 412 |
| Net profit | 90 | 85 | 77 | 73 | 54 |
| Net margin % | 15.7 | 15.9 | 14.9 | 15.3 | 13.1 |
| EPS (₹) | 5.47 | 5.13 | 4.65 | 4.42 | 3.27 |
Annual
| FY2026 | |
|---|---|
| Revenue | 1754 |
| Net profit | 247 |
| Net margin % | 14.1 |
| EPS (₹) | 14.95 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 19.1% in Mar 2026; debt to equity is 0.20.
Profitability · 1 years
Returns and margins
| Mar 2026 | |
|---|---|
| Return on equity % | 19.1 |
| Return on capital % | 24.3 |
| EBITDA margin % | 23.2 |
| Net margin % | 14.0 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Down 8.75 pts over 5 quarters.
Down 0.36 pts over 5 quarters.
Up 5.18 pts over 5 quarters.
+29 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|
| Promoter | 59.99 | 59.99 | 59.86 | 59.76 | 51.24 | -8.75 |
| FII | 9.37 | 7.99 | 7.54 | 7.52 | 9.01 | -0.36 |
| DII | 10.54 | 9.45 | 10.02 | 9.43 | 15.72 | +5.18 |
| Public | 20.1 | 22.57 | 22.58 | 23.3 | 24.02 | +3.92 |
Mutual fund holdings · Oct 2026
93 schemes hold this stock
64 the month before.
- Bajaj Finserv Healthcare Fund5.84% of NAV
- Kotak Manufacture In India Fund4.51% of NAV
- MOTILAL OSWAL SMALL CAP FUND4.27% of NAV
- Bajaj Finserv Small Cap Fund3.7% of NAV
- ICICI Prudential Life Cycle Fund 20363.33% of NAV
- CANARA ROBECO MANUFACTURING FUND3.24% of NAV
- HDFC Innovation Fund3.19% of NAV
- Motilal Oswal Focused Fund3.11% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for RUBICON are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about RUBICON
What is the RUBICON share price?
RUBICON (RUBICON) last closed at ₹1,722.30, up 3.86% on the day. Its 52-week range is ₹615.20 to ₹1,860.60.
What is the market cap of RUBICON?
RUBICON has a market capitalisation of about ₹27,508 crore. Its price-to-earnings ratio is 86.0.
How are RUBICON's latest results?
RUBICON reported revenue of ₹576 crore for Sep 2026, up 39.8% from a year earlier. Net profit was ₹90 crore (up 66.7% year on year). Return on equity was 19.1% in Mar 2026. Promoter holding was 51.24% in Sep 2026, down 8.75 points over 5 quarters.
Who owns RUBICON?
As of Sep 2026, shareholding was: Promoter 51.24%, FII 9.01%, DII 15.72%, Public 24.02%.
How many mutual funds hold RUBICON?
93 mutual fund schemes held RUBICON in October 2026. That compares with 64 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.